Approximately 30 million U.S. adults are believed to have sleep apnea, but only 6 million have been officially diagnosed.

Investors might want to bet on Inspire Medical Systems (INSP), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $215.54, a high ...

Inspire Medical Systems, Inc. ( NYSE: INSP) Q1 2025 Results Conference Call May 5, 2025 5:00 PM ET Ezgi Yagci - Vice President of Investor Relations Tim Herbert - President & Chief Executive Officer ...

Medical technology company Inspire Medical Systems (NYSE:INSP) announced in Q1 CY2025, with sales up 22.7% year on year to ...

offering a life-changing solution for patients with obstructive sleep apnea (OSA) who struggle with traditional CPAP therapy. Dr. Steven Landau The Inspire procedure is an advanced outpatient ...

Inspire Medical (NYSE: INSP) +, developer of a pacemaker-like device for treating sleep apnea, recently announced the hiring of two senior medical directors. Dr. Paul T. Hoff, an ...

The company continues to focus on innovation and patient outcomes in the sleep apnea treatment market ... Despite concerns about reimbursement rates for the Inspire 5 therapy, UBS believes the ease of ...

The company continues to focus on innovation and patient outcomes in the sleep apnea treatment ... rates for the Inspire 5 therapy, UBS believes the ease of the implant procedure could encourage ...